Phase 3 Icotrokinra Data Show Joint and Skin Improvements in Psoriatic Arthritis
Key Takeaways
Phase 3 ICONIC-PsA 1 met its primary endpoint, with 58% of biologic-naive patients receiving once-daily oral icotrokinra achieving ACR20 at Week 16, compared with 41% receiving placebo.
Icotrokinra demonstrated improvements in joint and skin disease, with 29% achieving ACR50 and 37% achieving PASI 90 at Week 16.
Joint and skin response rates increased numerically through Week 24, with no new safety signals reported. Icotrokinra remains investigational for psoriatic arthritis.
Once-daily oral icotrokinra (ICOTYDE; Johnson & Johnson) significantly improved joint disease activity compared with placebo in biologic-naive adults with active psoriatic arthritis (PsA), according to Phase 3 ICONIC-PsA 1 results presented at the American College of Rheumatology (ACR) Convergence 2026.
The investigational IL-23 receptor antagonist met its primary endpoint at Week 16, with 58% of patients receiving icotrokinra 200 mg achieving an American College of Rheumatology 20 (ACR20) response compared with 41% receiving placebo.
Icotrokinra Demonstrates Joint and Skin Responses Through Week 24
ICONIC-PsA 1 (NCT06878404) is a randomized, double-blind, placebo-controlled trial evaluating once-daily oral icotrokinra in biologic-naive adults with active PsA. Patients assigned to placebo crossed over to icotrokinra at Week 16.
At Week 16, ACR50 responses occurred in 29% of icotrokinra-treated patients versus 16% receiving placebo, while ACR70 responses occurred in 13% versus 5%, respectively.
Among patients with qualifying baseline skin involvement, 57% receiving icotrokinra achieved an Investigator's Global Assessment score of 0 or 1, compared with 14% receiving placebo. Psoriasis Area and Severity Index (PASI) 90 responses occurred in 37% versus 6%, respectively (nominal P < .001 for both skin endpoints).
By Week 24, response rates in the icotrokinra group increased numerically to 69% for ACR20, 40% for ACR50, and 18% for ACR70. PASI 90 responses reached 56%, while 64% achieved clear or almost clear skin.
Johnson & Johnson reported no new safety signals through Week 24. However, the placebo crossover at Week 16 limits longer-term comparative interpretation, and detailed adverse-event rates were not provided in the announcement.
“The significant joint responses observed in this study show the exciting potential for ICOTYDE, a targeted oral peptide therapy, to open an entirely new chapter in treating psoriatic arthritis with an oral option,” said Joseph F. Merola, MD, MMSc, a study commentator and paid Johnson & Johnson consultant.